DSM invests in innovative treatment against infectious diseases

07-Mar-2008

DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has made an equity investment in the Dutch company IQ Therapeutics B.V. The company develops antibody based products for biodefense and for the prevention and treatment of infectious diseases. DSM Venturing will hold a significant minority share in IQ Therapeutics.

The investment underlines DSM's position as a partner of choice for the pharma industry and expands the already existing relationship between both companies. IQ Therapeutics is a PER.C6® License Holder with DSM Biologics and Crucell for the production of its monoclonal antibodies.

In addition to the PER.C6® license and the new equity investment, IQ Therapeutics and DSM Biologics have a manufacturing agreement in place for process development, pilot manufacturing and GMP manufacturing of IQ Therapeutics' anti-anthrax antibody product. This product has been developed with IQ Therapeutics' proprietary technology for the generation of fully human antibodies from the blood of vaccinated donors.

The investment in IQ Therapeutics fits in DSM's strategy to fortify its presence in the biopharmaceutical market. This is the fastest growing market segment of the pharmaceutical market and is expected to more than triple in the next ten years.

This investment brings the total number of current company participations of DSM Venturing to 21. Venturing forms an integral part of DSM's open innovation approach, focused on teaming up with innovative players all over the world. The company has earmarked up to EUR 200 million for venturing investments until 2012.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous